Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 134)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 13
Gesamt: 390.076
Gesamt: 390.076
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
6,7700
USD
-4,24 %
-0,3000 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
17.05.24 · Accesswire  |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,25 | +63,04 | |
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 6,2500 | +24,75 | |
| 0,8200 | +15,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
FeedbackValeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
http://crweworld.com/article/news-provided-by-pr-newswire/24…
Antwort auf Beitrag Nr.: 57.144.006 von marty44 am 28.02.18 13:06:3328. Februar 2018
LAVAL, Quebec, 28. Februar 2018 / PRNewswire / - Valeant Pharmaceuticals International, Inc. (NYSE: VRX und TSX: VRX) ("Valeant") gab heute bekannt, dass Valeant Pharmaceuticals International, eine hundertprozentige indirekte Tochtergesellschaft von Valeant, wird den verbleibenden Nominalwert der ausstehenden vorrangigen unbesicherten Schuldverschreibungen von 7,00% im Jahr 2020 (die "Schuldverschreibungen") unter Verwendung von Kassenbeständen am 30. März 2018 zu tilgen und heute eine unwiderrufliche Rücknahmeerklärung für die Schuldverschreibungen zu erteilen. Die Schuldverschreibungen wurden ursprünglich im Jahr 2010 ausgegeben.
"Die Angleichung unserer Schulden bleibt eine Priorität für uns, während wir Valeant weiter transformieren", sagte Joseph C. Papa, Chairman und CEO von Valeant. "Aufgrund des starken operativen Cashflows können wir diese Schuldverschreibungen im Jahr 2020 in Höhe von mehr als 70 Millionen US-Dollar einlösen."
Am 28. Februar 2018 wird eine Kopie der unwiderruflichen Rücknahmeerklärung in Bezug auf die verbleibenden Schuldverschreibungen an die Inhaber der Schuldverschreibungen ausgegeben. Die Zahlung des Rücknahmepreises und die Rückgabe der Schuldverschreibungen erfolgen über die Einrichtungen der Depotführenden Treuhandgesellschaft gemäß den geltenden Verfahren der Depotführenden Treuhandgesellschaft. Name und Anschrift der Zahlstelle lauten wie folgt: Die Bank of New York Mellon Trust Company, N.A. c / o Die Bank of New York Mellon; 111 Sanders Creek Parkway, Ost Syracuse, N. Y. 13057; Attn: Erlösungseinheit; Tel .: 800-254-2826.
LAVAL, Quebec, 28. Februar 2018 / PRNewswire / - Valeant Pharmaceuticals International, Inc. (NYSE: VRX und TSX: VRX) ("Valeant") gab heute bekannt, dass Valeant Pharmaceuticals International, eine hundertprozentige indirekte Tochtergesellschaft von Valeant, wird den verbleibenden Nominalwert der ausstehenden vorrangigen unbesicherten Schuldverschreibungen von 7,00% im Jahr 2020 (die "Schuldverschreibungen") unter Verwendung von Kassenbeständen am 30. März 2018 zu tilgen und heute eine unwiderrufliche Rücknahmeerklärung für die Schuldverschreibungen zu erteilen. Die Schuldverschreibungen wurden ursprünglich im Jahr 2010 ausgegeben.
"Die Angleichung unserer Schulden bleibt eine Priorität für uns, während wir Valeant weiter transformieren", sagte Joseph C. Papa, Chairman und CEO von Valeant. "Aufgrund des starken operativen Cashflows können wir diese Schuldverschreibungen im Jahr 2020 in Höhe von mehr als 70 Millionen US-Dollar einlösen."
Am 28. Februar 2018 wird eine Kopie der unwiderruflichen Rücknahmeerklärung in Bezug auf die verbleibenden Schuldverschreibungen an die Inhaber der Schuldverschreibungen ausgegeben. Die Zahlung des Rücknahmepreises und die Rückgabe der Schuldverschreibungen erfolgen über die Einrichtungen der Depotführenden Treuhandgesellschaft gemäß den geltenden Verfahren der Depotführenden Treuhandgesellschaft. Name und Anschrift der Zahlstelle lauten wie folgt: Die Bank of New York Mellon Trust Company, N.A. c / o Die Bank of New York Mellon; 111 Sanders Creek Parkway, Ost Syracuse, N. Y. 13057; Attn: Erlösungseinheit; Tel .: 800-254-2826.
http://ir.valeant.com/news-releases/2018/02-28-2018-11453946…
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
February 28, 2018
LAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem the remaining $71 million aggregate principal amount of its outstanding 7.00% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on March 30, 2018 and will issue today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2010.
"Addressing our debt remains a priority for us as we continue to transform Valeant," said Joseph C. Papa, chairman and CEO, Valeant. "Due to strong operating cash flow, we are able to redeem these notes of more than $70 million due in 2020."
On Feb. 28, 2018, a copy of the irrevocable notice of redemption with respect to the remaining Notes will be issued to record holders of the Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the paying agent are as follows: The Bank of New York Mellon Trust Company, N.A. c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: 800-254-2826.
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
February 28, 2018
LAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem the remaining $71 million aggregate principal amount of its outstanding 7.00% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on March 30, 2018 and will issue today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2010.
"Addressing our debt remains a priority for us as we continue to transform Valeant," said Joseph C. Papa, chairman and CEO, Valeant. "Due to strong operating cash flow, we are able to redeem these notes of more than $70 million due in 2020."
On Feb. 28, 2018, a copy of the irrevocable notice of redemption with respect to the remaining Notes will be issued to record holders of the Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the paying agent are as follows: The Bank of New York Mellon Trust Company, N.A. c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: 800-254-2826.
Antwort auf Beitrag Nr.: 57.141.852 von marty44 am 28.02.18 10:06:50https://www.newsquantified.com/stock-report/vrx-valeant-phar…
Dem Kurs hat die news gestern wohl nicht geholfen.
Dem Kurs hat die news gestern wohl nicht geholfen.
Trading Spotlight
Antwort auf Beitrag Nr.: 57.140.490 von Berliner_Landstreicher am 28.02.18 08:29:35
LAVAL, Quebec, Feb. 27, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd., ("Kaken") to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.
Under the terms of the licensing agreement, Kaken has granted to Valeant an exclusive license to develop and commercialize topical products containing KP-470 to treat dermatological and rheumatological disorders and conditions. Valeant will have rights to develop and commercialize products with KP-470 in the United States, Canada, and Western and Eastern Europe.
"Investing in our core businesses and enhancing our pipeline for future growth is critical to the successful transformation of Valeant," said Joseph C. Papa, chairman and CEO, Valeant. "With an innovative mechanism of action, KP-470 has the potential to offer novel treatment options for the millions of people around the world who suffer from this debilitating disease."
"Medical dermatology remains a key therapeutic area of focus for the Company, and we are dedicated to developing new treatment options that complement our suite of medicines that treat psoriasis, as well as fungal infections, acne and atopic dermatitis," Papa continued.
Kaken will receive an upfront cash payment and has the potential to receive certain development-based milestone payments, as well as additional milestone payments based on the achievement of certain annual sales milestones. Additionally, Kaken will receive royalties on Valeant's net sales of the products.
Marktzugang für das japanische Produkt. Hoffentlich wird es auch zugelassen.
Zitat von Berliner_Landstreicher: Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
https://finance.yahoo.com/news/valeant-announces-licensing-a…
LAVAL, Quebec, Feb. 27, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd., ("Kaken") to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.
Under the terms of the licensing agreement, Kaken has granted to Valeant an exclusive license to develop and commercialize topical products containing KP-470 to treat dermatological and rheumatological disorders and conditions. Valeant will have rights to develop and commercialize products with KP-470 in the United States, Canada, and Western and Eastern Europe.
"Investing in our core businesses and enhancing our pipeline for future growth is critical to the successful transformation of Valeant," said Joseph C. Papa, chairman and CEO, Valeant. "With an innovative mechanism of action, KP-470 has the potential to offer novel treatment options for the millions of people around the world who suffer from this debilitating disease."
"Medical dermatology remains a key therapeutic area of focus for the Company, and we are dedicated to developing new treatment options that complement our suite of medicines that treat psoriasis, as well as fungal infections, acne and atopic dermatitis," Papa continued.
Kaken will receive an upfront cash payment and has the potential to receive certain development-based milestone payments, as well as additional milestone payments based on the achievement of certain annual sales milestones. Additionally, Kaken will receive royalties on Valeant's net sales of the products.
Marktzugang für das japanische Produkt. Hoffentlich wird es auch zugelassen.
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
https://finance.yahoo.com/news/valeant-announces-licensing-a…
https://finance.yahoo.com/news/valeant-announces-licensing-a…
Durchsuchen
Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
